Insilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too
Insilico Medicine has dosed the first patient with rentosertib, also known as ISM001-055 or INS018_055, in the GENESIS-IPF-3 Phase III clinical trial. The generative AI-discovered drug targets idiopathic pulmonary fibrosis, a severe lung disease. Clinical testing will evaluate lung-function decline over 52 weeks across 47 Chinese sites. Earlier findings indicate the experimental treatment made patients appear biologically younger by an average of three to four years, presenting a potential dual application in treating organ scarring and slowing aging markers.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Insilico Medicine dosed the first patient with rentosertib in the GENESIS-IPF-3 Phase III clinical trial at Peking Union Medical College Hospital.
- ✓ Shanghai Pulmonary Hospital enrolled its first patient on the same day as the Peking Union Medical College Hospital dosing.
- ✓ The Phase III trial is registered under the identifiers NCT07687459 and CTR20262475.
- ✓ Rentosertib is also known as ISM001-055 and INS018_055.
What changed
Insilico Medicine initiated the GENESIS-IPF-3 Phase III trial by dosing its first patients with rentosertib at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital.
Live updates
-
Insilico Doses First Patient in Phase III Trial for Rentosertib
Insilico Medicine has dosed the first patient with rentosertib, also known as ISM001-055 or INS018_055, in the GENESIS-IPF-3 Phase III clinical trial. The generative AI-discovered drug targets idiopathic pulmonary fibrosis, a severe lung disease. Clinical testing will evaluate lung-function decline over 52 weeks across 47 Chinese sites. Earlier findings indicate the experimental treatment made patients appear biologically younger by an average of three to four years, presenting a potential dual application in treating organ scarring and slowing aging markers.
Why it matters
Rentosertib represents a major milestone as the first generative AI-driven drug to enter a Phase III trial for idiopathic pulmonary fibrosis. The ongoing trials are tracking both traditional respiratory endpoints and biological age markers through proteomic aging clocks. Peking Union Medical College Hospital and Shanghai Pulmonary Hospital administered the initial doses on the same day.
What is confirmed
- Insilico Medicine dosed the first patient with rentosertib in the GENESIS-IPF-3 Phase III clinical trial at Peking Union Medical College Hospital.
- Shanghai Pulmonary Hospital enrolled its first patient on the same day as the Peking Union Medical College Hospital dosing.
- The Phase III trial is registered under the identifiers NCT07687459 and CTR20262475.
- Rentosertib is also known as ISM001-055 and INS018_055.
- The Phase III study will test lung-function decline over 52 weeks across 47 Chinese sites.
Still unconfirmed
- The experimental lung disease drug rentosertib made patients appear biologically younger by an average of three to four years in a new study.
What to watch next
- Results from the 52-week GENESIS-IPF-3 trial across the 47 Chinese clinical sites.
- Further data regarding the geroprotective effects and biological age reversal markers of rentosertib.
confidence 100%Sources used for this update (5)
- nypost.com — Drug developed for lung disease may slow biological aging in surprising ‘bonus’
- finance.yahoo.com — Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
- www.rttnews.com — Insilico Medicine Doses First Patient In GENESIS-IPF-3 Phase III Trial
- www.news-medical.net — Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis
- www.clinicaltrialvanguard.com — Insilico Medicine Begins Phase III Trial of AI-Discovered Drug Rentosertib for IPF
-
AI-Designed Fibrosis Drug Reverses Biological Age Markers in Study
Insilico Medicine reports that an AI-generated drug candidate intended for fibrosis can reverse biological age markers and slow aging. Early data from a clinical study indicates the drug candidate impacts biological age, while a phase 2a trial has integrated proteomic aging clocks to allow for simultaneous geroprotective assessment. The company's Co-CEO believes the fibrosis treatment possesses the potential to reverse aging processes. These findings suggest a dual application for the AI-discovered compound in treating specific organ scarring and extending healthy lifespan.
Why it matters
AI-driven drug discovery aims to reduce the time and cost of finding new therapeutic compounds. By targeting fibrosis, the drug addresses the buildup of scar tissue in organs. The addition of aging clocks to clinical trials allows researchers to measure biological age independently of chronological age.
What is confirmed
- An AI-generated drug candidate can reverse biological age markers.
- Early data indicates an AI-generated drug could slow aging.
- A phase 2a clinical trial integrated proteomic aging clocks for geroprotective assessment.
Still unconfirmed
- Insilico's Co-CEO believes the fibrosis drug can reverse aging.
What to watch next
- Peer-reviewed results from the phase 2a clinical trial regarding geroprotective effects.
- Confirmation of the specific biological markers reversed by the AI-designed candidate.
confidence 90%Sources used for this update (5)
- The New York Times — Early Data Indicates an A.I.-Generated Drug Could Slow Aging
- Nature — Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment
- Bloomberg.com — AI-Discovered Drug Reverses Aging Markers In Study, Biotech Says
- wsj.com — Insilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too
- News-Medical — AI-designed drug candidate reverses biological age in clinical study
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community